Zydus Cadila

Letter opening FDA clinical hold
Manufacturing

FDA slams 3 Indian drugmakers in flurry of recent Form 483s

The FDA hit three Indian drugmakers with Form 483s after inspections uncovered unsanitary conditions, broken equipment and poor recordkeeping.
Joseph Keenan Apr 16, 2024 8:45am
Revlimid bottle

BMS, generics companies face new suit over Revlimid 'monopoly'

Nov 22, 2022 11:38am
India flag

Tough decisions for Indian pharmas who do business with Russia

Mar 9, 2022 9:38am
Teva

Teva launches Revlimid generic, the first to do so in U.S.

Mar 7, 2022 11:11am